LDLotte Dammertz

Lotte Dammertz

*This is an algorithmically generated author record based on publicly available information.

Lotte Dammertz has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Anette Schrag

    Department of Clinical and Movement Neurosciences, University College London, London, UK

    1 shared publication
  • Anne Neubert

    Department of Orthopedics and Traumatology, University Hospital and Medical Faculty, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

    1 shared publication
  • Carolina Pioch

    Department of Health Care Management, Technical University of Berlin, Berlin, Germany

    1 shared publication
  • Claudia Kohring

    Department of Epidemiology and Healthcare Atlas Central Research Institute of Ambulatory Health Care in Germany Berlin Germany

    1 shared publication
  • Enno Swart

    Affiliation Institute of Social Medicine and Health Systems Research, Otto von Guericke University Magdeburg, Magdeburg, Germany

    1 shared publication
  • Hanna Ermann

    Affiliation Department of Health Care Management, Technical University of Berlin, Berlin, Germany

    1 shared publication

Latest Publications

  • Open Access

    Selecting indicators for the measurement of low-value care using German claims data: A three-round modified Delphi panel

    by Carolina Pioch, Anne Neubert, Lotte Dammertz, Hanna Ermann, Meik Hildebrandt, Peter Ihle, Monika Nothacker, Udo Schneider, Enno Swart, Reinhard Busse, et al.

    By reducing healthcare services that offer little benefit or potential harm to patients (low-value care), resources can be redirected towards more adequate treatments, improving healthcare efficiency and patient outcomes. This study aimed to systematically incorporate clinical expertise across medical disciplines through a Delphi process to establish indicators for measuring low-value care, ensuring their acceptance by medical societies, the broader medical community, and patients. We developed two versions (one with higher sensitivity and one with higher specificity) for almost each of the 42 indicators identified as potentially measurable in a previous systematic review. We conducted a three-round modified Delphi panel based on the RAND/UCLA appropriateness methodology, with 62 experts from 52 Scientific Medical Societies and professional organisations, and patient representatives. In round one, each indicator was rated for its ability to indicate low-value healthcare and its measurability in German claims data. This was followed by an online discussion in round two. The indicators were then modified based on expert feedback and re-assessed in round three. As a result, 24 indicators were deemed appropriate for measuring low-value care, covering areas such as pharmaceuticals, diagnostic tests, screening, and treatment. For example, one indicator identified patients with cancer who received chemotherapy in the last month of life. These indicators will help identify healthcare services that may require policy-level interventions to improve the quality of care. However, most low-value care indicators can only be measured in German claims data if documentation requirements for relevant information are expanded.


  • Falling incidence of Parkinson's disease in Germany

    by Lotte Dammertz, Anette Schrag, Jens Bohlken, Joachim Heuer, Claudia Kohring, Julia Schorlemmer, Manas K. Akmatov, Jörg Bätzing, Jakob Holstiege

    Background and purpose: Idiopathic Parkinson's disease (IPD) is a progressive neurodegenerative disorder that is strongly associated with age. The aim of the present study was to describe current sex‐ and age‐specific trends and regional differences in the incidence of IPD diagnosed in older people in Germany.Methods: This study was based on nationwide outpatient claims and drug prescription data from the German Statutory Health Insurance, covering approximately 87% of the general population. We conducted a cohort study in patients aged 50 years or older with observation time of at least 4 years. To assess the robustness of nationwide annual IPD incidence trends from 2013 to 2019, three case definitions with varying levels of stringency regarding coded outpatient diagnoses and drug prescriptions were applied.Results: In 2019, the population at risk comprised 30,575,726 persons. Using the primary and most specific case definition, annual age‐ and sex‐standardized cumulative IPD incidence decreased stepwise from 137 (2013) to 106 (2019) new cases per 100,000 persons. The decline in incidence was seen in both sexes, in all age groups and in the majority of German regions. The relative decrease (2013–2019) in the annual age‐ and sex‐standardized IPD incidence varied from 23% to 28% among case definitions.Conclusion: Our findings indicate a nationwide decline in the age‐ and sex‐standardized incidence of IPD from 2013 to 2019 in Germany. This trend was consistent using different case definitions. Further research is needed to elucidate the factors underlying this trend.